Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
June 07, 2024 16:05 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
June 05, 2024 19:53 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
June 03, 2024 16:09 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
June 03, 2024 07:30 ET
|
Structure Therapeutics Inc.
GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the...
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
May 09, 2024 16:05 ET
|
Structure Therapeutics Inc.
Topline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human...
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
March 08, 2024 16:05 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
March 08, 2024 08:30 ET
|
Structure Therapeutics Inc.
Topline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in...
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
December 18, 2023 07:30 ET
|
Structure Therapeutics Inc.
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0%...
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023 16:10 ET
|
Structure Therapeutics Inc.
Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and...
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
September 29, 2023 07:32 ET
|
Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...